Article: Nicotinamide Riboside Restores Mitochondrial Function in Alpers’ Syndrome: Preclinical Findings

PrevNext
Mitochondrial Health Neurological Health Orphan Disease Preclinical

Nicotinamide Riboside Restores Mitochondrial Function in Alpers’ Syndrome: Preclinical Findings

Synopsis

Alpers' syndrome is a devastating early-onset neurodegenerative disorder caused by POLG mutations impairing mitochondrial DNA replication. Patient-derived iPSCs were used to create brain organoids and neural stem cells, which replicated the mitochondrial and neuronal defects seen in patients. Treatment with nicotinamide riboside (NR) improved mitochondrial function in these organoids, suggesting NR could be a potential therapeutic strategy for Alpers' syndrome and other mitochondrial disorders with similar mechanisms.

Journal

International Journal of Biological Sciences

Share

Read more

Kidney Disease

Nicotinamide Riboside Restores NAD+ and Improves Mitochondrial Function in HIV-Nephropathy: Preclinical Findings

SynopsisHIV disease remains prevalent in the United States and especially in sub-Saharan Africa. In mice with HIV-associated kidney disease (HIVAN), their kidney cells showed mitochondrial dysfunct...

Read more
Cardiovascular Health

Nicotinamide Riboside Restores NAD+ and Improves Heart and Brain Function in Leigh Syndrome: Preclinical Findings

SynopsisMice lacking the mitochondrial complex I subunit Ndufs4 develop Leigh syndrome (LS), marked by serious brain and heart problems. This study found these mice have slow, irregular heartbeats ...

Read more